Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Bristol-Myers Squibb
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with type 2 diabetes mellitus
HbA1c ≥6.5%. (based on the last measured and documented laboratory measurement within 6 months)
High risk for CV events -Established cardiovascular disease and/or multiple risk factors
You may not be if
Current or previous (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics
Acute vascular event \<2months prior to randomisation
Clareo Health | Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
